

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT SHARE PURCHASE PURSUANT TO THE 2021 H SHARE AWARD AND TRUST SCHEME

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”) on a voluntary basis.

Reference is made to the announcement of the Company dated August 30, 2021 (the “**Announcement**”) and the circular of the Company dated September 7, 2021 (the “**Circular**”) in relation to the 2021 H Share Award and Trust Scheme adopted by the Company on September 23, 2021. Unless otherwise defined herein, capitalized terms used herein shall have the same meanings as those defined in the Announcement and the Circular.

Pursuant to the 2021 H Share Award and Trust Scheme, (i) from August 25, 2023 and up to the date of this announcement, the Trustee has purchased a total number of 817,000 Shares on the market at prices in the range of HK\$7.30 to HK\$9.76; and (ii) as at the date of this announcement, the Trustee has purchased a total number of 3,541,500 Shares on the market with average market price of HK13.63.

Pursuant to the 2021 H Share Award and Trust Scheme, the Company may instruct the Trustee to make further purchases of additional 6,430,500 Shares and may make further announcements on the status of the 2021 H Share Award and Trust Scheme, including the number and price of the Shares purchased, from time to time. The purchase of the Shares was funded by the Company’s own financial resources other than proceeds from the listing of the Shares on the Main Board of the Stock Exchange.

In the meantime, the Company is actively considering initiating Share repurchases in accordance with the Listing Rules, subject to foreign exchange remittance approval with the relevant PRC regulatory authorities and necessary Shareholders' approval for certain proposed amendments to the Articles of Association in relation to Share repurchases.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, September 25, 2023

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.